| 76.28 BATS BZX Real-Time Price As of 3:32pm ET |  -2.08 / -2.65%Today’s Change | 50.71 Today|||52-Week Range 84.37 | +34.63% Year-to-Date |
| Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report? Aug 15 / Zacks.com - Paid Partner Content |
| Previous close | 78.36 |
| Today’s open | 78.14 |
| Day’s range | 76.28 - 78.80 |
| Volume | 217,643 |
| Average volume (3 months) | 928,502 |
| Market cap | $13.4B |
| Earnings growth (last year) | -60.51% |
| Earnings growth (this year) | +6.32% |
| Earnings growth (next 5 years) | +23.00% |
| Revenue growth (last year) | +35.76% |
| P/E ratio | NM |
| Price/Sales | 13.64 |
| Price/Book | 9.96 |
| Today’s change | Today’s % change | |
|---|---|---|
| MYLMylan NV | -0.58 | -3.05% |
| IONSIonis Pharmaceutical... | +0.17 | +0.25% |
| ALNYAlnylam Pharmaceutic... | -0.65 | -0.79% |
| GLPGGalapagos NV | -2.51 | -1.51% |
| Next reporting date | November 4, 2019 |
| EPS forecast (this quarter) | -$0.36 |
| Annual revenue (last year) | $654.7M |
| Annual profit (last year) | -$222.7M |
| Net profit margin | -34.01% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Clay B. Siegall |
Chief Financial & Accounting Officer Todd E. Simpson |
Corporate headquarters Bothell, Washington |
